BDX

Becton, Dickinson and Company — ticker BDX — is classified under the Healthcare sector, specifically in the Medical - Instruments & Supplies industry. In plain terms, it is a global medical technology company that develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. Its solutions target medication management, patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology, infectious-disease and cancer diagnostics, and cellular research. As of September 30, 2025, BD operated through three worldwide segments: BD Medical, BD Life Sciences and BD Interventional.

The financial profile of a roughly $49.6 billion company earning a 4.5% net margin and generating a 3.8% return on equity is telling. Those numbers do not point to a high-margin, capital-light compounder. Instead, they suggest a durable but capital-intensive business where regulatory compliance, scale manufacturing, price-sensitive hospital procurement and ongoing deal integration compress current returns. The implied competitive position is one of breadth, switching costs and regulatory relationships rather than outsized pricing power.

BDX currently carries a market cap of $49.6 billion and trades at a P/E of 54.2, supported by a net margin of 4.5% and ROE of 3.8%. A 54.2x multiple is notably disconnected from the company’s current profitability profile; it implies the market is pricing in a future earnings inflection, restructuring benefits or strategic optionality rather than present earnings power. The stock’s beta is 0.26, which is consistent with a defensive healthcare supplier that moves less than the broad market. As of the latest snapshot, the price was $180.07, RSI was 49.0 and the 50-day EMA sat at $174.48. In short, the valuation looks stretched relative to current margins and returns, and would require execution against the strategic plan to justify itself numerically.

BD’s most recent 10-K outlines a company remaking its portfolio. Effective October 1, 2025, BD reorganized into five separately-managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. The filing also highlights the Reverse Morris Trust combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close around the end of the first quarter of calendar-year 2026. BD expects to receive approximately $4 billion in cash and for its shareholders to own roughly 39.2% of the combined company once that transaction closes.

On the acquisition side, BD completed the $3.914 billion purchase of Edwards Lifesciences’ Critical Care product group in September 2024, integrating it as BD Advanced Patient Monitoring within BD Medical. The company has also been pruning: it divested its Diabetes Care business as Embecta Corp. in April 2022 and sold the Interventional segment’s Surgical Instrumentation platform in August 2023, recording a pre-tax gain of approximately $268 million on the latter.

Operationally, BD has manufacturing outside the United States in 18 countries across EMEA, Greater Asia, Latin America and Canada. The 10-K notes that foreign economic conditions and exchange-rate fluctuations have caused profitability related to foreign revenues to fluctuate more than domestic profitability, flagging currency as a real operational risk.

The Medical - Instruments & Supplies industry sits at the intersection of healthcare regulation, global manufacturing and hospital economics. Companies in this space are exposed to FDA and foreign-health-authority approvals, reimbursement policy, group purchasing organization pricing pressure, and hospital capital-spending cycles. Because the industry relies on disposables, plastics, electronic components and global logistics, it is also sensitive to commodity input costs, freight rates and supply-chain disruptions. Trade policy matters: tariffs or import/export restrictions on finished devices and components can move margins. Currency risk is especially relevant for multinational suppliers with wide international footprints, and BD’s 10-K explicitly flags that exchange-rate swings have made foreign-revenue profitability more volatile than domestic profitability.

Recent news frames BDX as both an execution story and a valuation debate:

• On September 14, 2026, PR Newswire reported that “BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview,” pointing to automation and pharmacy-care innovation as a forward-looking theme.
• On September 10, 2026, GuruFocus asked “Is BDX Overvalued? DCF Says Worth $157,” and on September 2, 2026, the same outlet published “BDX DCF Analysis: Intrinsic Value $157 vs Price $187.” With the stock at $180.07 as of the latest snapshot, it still sits above that discounted-cash-flow indication.
• On September 9, 2026, Seeking Alpha carried the transcript of Becton, Dickinson and Company presenting at the Wells Fargo 21st Annual Healthcare Conference, where management likely discussed the five-segment reorganization, the Waters transaction and integration of the Edwards Critical Care acquisition.

Together, these items underscore a company investing in longer-term automation while the market debates whether the current share price fully reflects the strategic plan.

BDX has an unusually strong recent earnings record. Over the last eight reported quarters, it beat consensus earnings estimates 8 out of 8 times, a 100% beat rate, with an average surprise of 8.2%. The average 5-day price move in the five trading days after earnings across those quarters was +3.66%, classified as an upward post-earnings drift.

The last four reports, listed most recent first, show consistent beats but mixed immediate price action:

• August 6, 2026: actual EPS $3.23 versus estimate $3.14 (2.9% surprise, beat); next-day move -0.12%, 5-day move +2.77%.
• May 7, 2026: actual EPS $2.90 versus estimate $2.78 (4.3% surprise, beat); next-day move -2.5%, 5-day move -5.74%.
• February 9, 2026: actual EPS $2.91 versus estimate $2.21 (31.7% surprise, beat); next-day move +5.3%, 5-day move +8.8%.
• November 6, 2025: actual EPS $3.96 versus estimate $3.92 (1% surprise, beat); next-day move +0.25%, 5-day move +8.82%.

The positive average drift is driven by the large post-earning moves in November 2025 and February 2026, offsetting the negative drift seen after the May 2026 report. The next scheduled earnings date is November 5, 2026, before the open, with the current consensus EPS estimate at $4.06. The 100% beat rate and 8.2% average surprise suggest the market’s real expectation may run above the published consensus, although recent post-announcement reactions have been inconsistent enough that a beat has not always produced a short-term rally.